This study will investigate the health effects of a community environmental remediation program on asthma control and outcomes. The long-term goal of this study is to inform future prospective studies exploring environmental interventions in children and adolescents with poorly controlled severe asthma.Objectives:Recruit and complete weatherization services for at least 20 families per year over the next 5 yearsDetermine the percentage reduction in acute care events for patients of patients whose homes undergo weatherizationDetermine whether the weatherization program shows improvements in quality of lifeTHIS STUDY IS ENROLLING BY INVITATION ONLY - Subjects will be recruited through the Riley Division of Pediatric Pulmonology, Allergy and Sleep Medicine. Subjects meeting inclusion criteria will be approached during the clinic visit and/or via telephone. 

The purpose of this study protocol is to collect blood samples and relevant medical data from the intended use population presenting with a clinical suspicion of acute heart failure (i.e. new-onset heart failure or worsening symptoms suggestive of decompensated or exacerbated heart failure).  Blood samples are collected to support assay verification and the assay’s regulatory approval of natriuretic peptide assays on low volume platforms.  The objective of this study is to collect blood samples and These samples will be tested to verify method comparison for each of the IUO natriuretic peptide assays (Access NT-proBNP Assay (P/N C71977) and Access BNP II Assay (P/N D24688)) between Access 2, DxC 500i and the predicate device DxI 9000 Access Immunoanalyzer under separate protocols.THIS STUDY IS ENROLLING BY INVITATION ONLY - Only adult patients presenting with a clinical suspicion of acute heart failure (i.e. new-onset heart failure or worsening symptoms suggestive of decompensated or exacerbated heart failure) are considered for this study and will be invited by the research team for participate.

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).Study goals:To evaluate the effect of EFX compared to placebo on achieving NASH/MASH resolution AND fibrosis regression at Week 52 (in Cohort 1 only)To evaluate the effect of EFX compared to placebo on all-cause mortality and liver-related clinical outcomes as measured by the time to first occurrence of any of the predefined, adjudicated events in subjects with NASH/MASH and fibrosisTHIS STUDY IS ENROLLING BY INVITATION ONLY

The goal of this proposal is to create an opportunity and a platform for rural AYA survivors to inform the medical community which barriers impact their access to healthcare.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential subjects will be recruited from the Family Medicine Clinic in Jasper, Indiana, the Good Samaritan Clinic in Vincennes, Indiana, Ascension St Vincent Hospital in Evansville, and a list of AYA cancer survivors obtained from the Regenstrief Institute EMR files. Study personnel will work with the clinicians in all these facilities to obtain the names of patients who have had a diagnosis of cancer and are off treatment. The study team will either approach the families at clinic or call if they have agreed to be contacted for research. In addition, the research study team will make calls from the list obtained by Regenstrief for recruitment.  Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact theIU Clinical Trials Office at Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to learn more about thoughts and experiences completing the FAST, a tool healthcare providers us as part of a fertility consult. This information may help us better incorporate the FAST into fertility consults at other healthcare institutions. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The XTRACT Registry is a prospective, single arm multicenter study on the use of on the Rotarex(TM) Rotational Excisional Atherectomy System.THIS STUDY IS ENROLLING BY INVITATION ONLY